17.10.2023 - GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) - Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric . Seite 1
GARDEN CITY, N.Y., Oct. 16, 2023 Beyond Air, Inc. , a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide to.
Moreover, the 36-month beta value for XAIR is -0.29. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.” The average price recommended by analysts for Beyond Air Inc (XAIR)
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. that is developing ultra-high concentration nitric oxide as an immunotherapeutic.
Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.